GlassScriptPhysician profile
Alyssa A Bobinger
NPI 1801137476
$1,998.71
in general payments reported to CMS, 2019-2025
11 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $167 · 2024: $1,273 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.72 |
| Education | $369.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $785.33 | 2024-2025 | Xospata, Cresemba |
| Celgene Corporation | $372.99 | 2023-2025 | Reblozyl, Breyanzi, Onureg |
| E.R. Squibb & Sons, L.L.C. | $349.44 | 2023-2024 | Reblozyl |
| Sanofi-Aventis U.S. LLC | $202.19 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $58.78 | 2024-2025 | Clonoseq |
| Daiichi Sankyo INC. | $49.56 | 2024 | Vanflyta |
| Legend Biotech USA INC. | $45.77 | 2024-2025 | Carvykti |
| Karyopharm Therapeutics INC. | $44.80 | 2024-2025 | Xpovio |
| Janssen Scientific Affairs, LLC | $41.96 | 2025 | Darzalex, Carvykti, Talvey |
| Incyte Corporation | $26.12 | 2025 | Niktimvo |
| Genzyme Corporation | $21.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Bobinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.